Skip to Content
Merck
CN

14401

Zinc

≥99%, powder (coarse)

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
Zn
CAS Number:
Molecular Weight:
65.39
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-175-3
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

vapor pressure

1 mmHg ( 487 °C)

assay

≥99%

form

powder (coarse)

resistivity

5.8 μΩ-cm, 20°C

bp

907 °C (lit.)

mp

420 °C (lit.)

density

7.133 g/mL at 25 °C (lit.)

cation traces

As: ≤0.2 mg/kg, Cd: ≤50 mg/kg, Fe: ≤50 mg/kg, Pb: ≤100 mg/kg, Sn: ≤10 mg/kg

SMILES string

[Zn]

InChI

1S/Zn

InChI key

HCHKCACWOHOZIP-UHFFFAOYSA-N

Application

Used as reducing agent; used for preparation of organozinc reagents; used as catalyst for cross coupling

pictograms

Environment

signalword

Warning

hcodes

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1

Storage Class

13 - Non Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kise, N.; Ueda, N. et al
Tetrahedron Letters, 42, 2365-2365 (2001)
Paul, S.; Nanda, P.; Gupta, R.; Loupy, A.
Synthesis, 2872-2872 (2003)
Neo, A. G.; Delgado, J. et al.
Tetrahedron Letters, 46, 23-23 (2005)
A viewpoint about the treatment of Wilson's disease.
Abdul Qayyum Rana et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 40(4), 612-614 (2013-06-22)
Sara Eyal et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 50(5), 798-806 (2009-05-01)
Studies in rodents indicate that the disruption of P-glycoprotein (P-gp) function increases drug distribution into the developing fetus and organs such as the brain. To simultaneously and serially evaluate the effect of P-gp activity and inhibition on the tissue distribution

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service